Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Stock Price Passes Below 50-Day Moving Average – Here’s Why

Bayer Aktiengesellschaft (OTCMKTS:BAYRY)’s stock price crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $11.02 and traded as low as $10.30. Bayer Aktiengesellschaft shares last traded at $10.38, with a volume of 586,457 shares changing hands.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. DZ Bank raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. Zacks Research upgraded Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a report on Friday, May 8th. UBS Group raised Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research report on Monday, March 16th. Finally, Jefferies Financial Group upgraded Bayer Aktiengesellschaft to a “hold” rating in a report on Friday, May 29th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

Bayer Aktiengesellschaft Price Performance

The company has a market capitalization of $41.51 billion, a P/E ratio of -16.50, a P/E/G ratio of 3.44 and a beta of 0.59. The firm’s fifty day moving average is $10.99 and its 200 day moving average is $11.43. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.63 and a current ratio of 1.05.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.15. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.61%. The business had revenue of $15.73 billion during the quarter, compared to the consensus estimate of $15.77 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, analysts predict that Bayer Aktiengesellschaft will post 1.25 earnings per share for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.